| Literature DB >> 32243061 |
Mingfen Lai1, Guiju Liu2, Ruijun Li2, Hua Bai2, Jizhi Zhao2, Peng Xiao2, Jiazhuan Mei2.
Abstract
The aim of the study was to research the biological functions of circRNA (hsa_circ_0079662) and its underlying mechanism in colorectal cancer. Drug-resistant cell lines (HT29-LOHP, HCT116-LOHP, HCT8-LOHP) were separately dealt with oxaliplatin concentration gradient (0.1-10 μmol/L). Real-time PCR, Western blotting, dual-luciferase assay, miRNA pull-down assay, coimmunoprecipitation and ELASA were performed to explore the mechanism of chemotherapy drug oxaliplatin resistance in CRC. The results showed that the expression of hsa_circ_0079662 was increased in drug-resistant cell lines by RT-PCR. The expression of HOXA9, TRIP6, Vcam-1, VEGFC, MMP3, MMP9 and MMP14 was higher by Western blotting. Interaction between HOXA9 and TRIP6 in CO-IP detection. Additionally, the cytokines TNF-α, IL-1 and IL-6 were also found. In conclusion, hsa_circ_0079662, as a ceRNA binding with hsa-mir-324-5p, can regulate target gene HOXA9 and induced the mechanism of chemotherapy drug oxaliplatin resistance in CRC through the TNF-α pathway in human colon cancer.Entities:
Keywords: HOXA9; Hsa_circ_0079662; TNF-α pathway; ceRNA; colorectal cancer
Year: 2020 PMID: 32243061 PMCID: PMC7205783 DOI: 10.1111/jcmm.15122
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Figure 1Hsa_circ_0079662 is up‐regulated in drug‐resistant CRC cell lines
Figure 2Hsa_circ_0079662 promotes growth of drug‐resistant CRC cell lines
Figure 3Hsa_circ_0079662 in hsa‐mir‐324‐5p treated cells, significantly reversed the growth‐inhibitory role. ****P < .001
Figure 4Hsa‐mir‐324‐5p treatment decreased cell growth of cells. *P < .05
Figure 5The expression of cytokines TNF‐α, IL‐1 and IL‐6 was increased in drug‐resistant CRC. *P < .05